



Patent Docket P1007R1C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  
Avi J. Ashkenazi  
Serial No.: 10/081,280  
Filed: February 21, 2002  
For: APO-2LI AND APO-3 POLYPEPTIDES

Group Art Unit: 1653

Examiner: to be assigned

Confirmation No. 2465

**CERTIFICATE OF EXPRESS MAILING**  
Express Mail Number: EV016055917US  
I hereby certify that this correspondence is being deposited with the United States Postal Service Express Mail Post Office to Addressee service under 37 CFR 1.10 on the date indicated below and is addressed to Assistant Commissioner of Patents, Washington, D.C. 20231.

May 7, 2002

Mona Beltran

**TRANSMITTAL LETTER**

**EV016055917US**

Assistant Commissioner of Patents  
Washington, D.C. 20231

Sir:

Transmitted herewith are the following documents:

1. Information Disclosure Statement
2. Form PTO-1449 with 6 references.
3. Postcard

In the event any additional fees are due in connection with the filing of these documents, the Commissioner is authorized to charge such fees to our Deposit Account No. 07-0630.

Respectfully submitted,

GENENTECH, INC.

By:   
Diane L. Marschang  
Reg. No. 35,600  
Telephone No. (650) 225-5416



09157

PATENT TRADEMARK OFFICE



Patent Docket P1007R1C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  Avi J. Ashkenazi  Serial No.: 10/081,280  Filed: February 21, 2002  For: APO-2LI AND APO-3 POLYPEPTIDES	Group Art Unit: 1653  Examiner: Not yet assigned  Confirmation No. 2465  <b>CERTIFICATE OF EXPRESS MAILING</b> Express Mail Number: EV016055917-US  I hereby certify that this correspondence is being deposited with the United States Postal Service, Express Mail Post Office to Address service under 37 CFR 1.10 on the date indicated below and is addressed to "Assistant Commissioner of Patents, Washington, D.C. 20231".  May 7, 2002  <i>Mona Beltran</i> Mona Beltran
---	--

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner of Patents  
Washington, D.C. 20231

Sir:

Applicant submits herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

(X) **37 CFR §1.97(b)**

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); or
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR§1.491, or
- before the mailing of the first Office action on the merits; or
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

A list of the patents or publications is set forth on the attached revised Form PTO-1449 (Modified). A copy of the references identified as item numbers 1, 26, 27, 30, 138, and 284 on PTO-1449 are supplied herewith. Those patents or publications which are marked with an asterisk (\*) in the attached PTO-1449 form are not supplied because they were previously cited by or submitted

to the Office in prior application Serial No. 08/829,270, filed March 31, 1997 and relied upon in this application for an earlier filing date under 35 USC §120.

Applicant also wishes to bring to the Examiner's attention the following co-pending US applications filed by Applicant and which disclose subject matter relating to the instant application: 08/625,328 filed April 1, 1996; 08/800,699 filed February 14, 1997; 09/884,733 filed June 19, 2001; 08/828,683 filed March 31, 1997; 09/993,234 filed November 19, 2001; 10/112,793 filed March 28, 2002; 08/928,069 filed September 11, 1997; and 10/112,193 filed March 28, 2002.

A concise explanation of relevance of the items listed on PTO-1449 is:

(X) not given

0 given for each listed item

0 given for only non-English language listed item(s) (Required)

0 in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR §1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

In the event that the Office determines a fee to be due where none is specifically authorized in this paper, the U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p).

Respectfully submitted,

GENENTECH, INC.

By: Diane L. Marschang  
Diane L. Marschang  
Reg. No. 35,600  
Telephone No. (650) 225-5416

Date: May 7, 2002



09157

PATENT TRADEMARK OFFICE



Sheet 01 of 15

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.  
P1007R1C1

Serial No.  
10/081,280

**LIST OF DISCLOSURES CITED BY APPLICANT**

(Use several sheets if necessary)

Applicant  
Ashkenazi

Filing Date  
21 Feb 2002

Group  
1653

**U.S. PATENT DOCUMENTS**

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
	1	2002/0009773A1	24.01.02	Yu, G. et al.			
	* 2	3,691,016	12.09.72	Patel, R.			
	* 3	3,969,287	13.07.76	Jaworek et al.			
	* 4	4,179,337	18.12.79	Davis et al.			
	* 5	4,195,128	25.03.80	Hildebrand et al.			
	* 6	4,229,537	21.10.80	Hodgins et al.			
	* 7	4,247,642	27.01.81	Hirohara et al.			
	* 8	4,301,144	17.11.81	Iwashita et al.			
	* 9	4,330,440	18.05.82	Ayers et al.			
	* 10	4,342,566	03.08.82	Theofilopoulos et al.			
	* 11	4,399,216	16.08.83	Axel et al.			
	* 12	4,419,446	06.12.83	Howley et al.			
	* 13	4,496,689	29.01.85	Mitra, G.			
	* 14	4,601,978	22.07.86	Karin, M.			
	* 15	4,640,835	03.02.87	Shimizu et al.			
	* 16	4,670,417	02.06.87	Iwasaki et al.			
	* 17	4,676,980	30.06.87	Segal et al.			
	* 18	4,736,866	12.04.88	Leder et al.			
	* 19	4,791,192	13.12.88	Nakagawa et al.			
	* 20	4,816,567	28.03.89	Cabilly et al.			
	* 21	4,870,009	26.09.89	Evans et al.			
	* 22	4,965,199	23.10.90	Capon et al.			
	* 23	5,010,182	23.04.91	Brake et al.			
	* 24	5,364,934	15.11.94	Drayna et al.			
	* 25	6,153,402	28.11.00	Yu et al.			
	26	60/013,285	12.03.96	Yu et al.			
	27	60/028,711	17.10.96	Yu et al.			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	No
	* 28	0,003,089 A1	25.07.79	EPO (ENGLISH ABSTRACT ATTACHED)				
	* 29	036,766	30.09.81	EPO				
	30	036,776 A2	30.09.81	EPO				
	* 31	073,657	09.03.83	EPO				
	* 32	117,058 A2	29.08.84	EPO				
	* 33	117,060 A2	29.08.84	EPO				

Examiner

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449	U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1007R1C1	Serial No. 10/081,280
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		Applicant Ashkenazi	
		Filing Date 21 Feb 2002	Group 1653

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Country	Class	Subclass	Translation Yes	No
*	34 125,023 A1	14.11.84	EPO				
*	35 173,494	05.03.86	EPO				
*	36 278,776	17.08.88	EPO				
*	37 307,247 B1	15.03.89	EPO				
*	38 321,196	21.06.89	EPO				
*	39 362,179 A2	04.04.90	EPO				
*	40 417,563 B1	20.03.91	EPO (ENGLISH ABSTRACT ATTACHED)				
*	41 510,691 ✓	28.10.92	EPO				
*	42 911,633 A1	28.04.99	EPO				
*	43 266,710	12.04.89	GERMANY (ENGLISH ABSTRACT ONLY)				
*	44 00/64465	02.11.00	PCT				
*	45 93/08829		PCT				
*	46 WO 87/05330	11.09.87	PCT				
*	47 WO 89/02922	06.04.89	PCT				
*	48 WO 89/05859	29.06.89	PCT				
*	49 WO 90/13646	15.11.90	PCT (ENGLISH ABSTRACT ATTACHED)				
*	50 WO 91/00358	10.01.91	PCT				
*	51 WO 91/00360		PCT				
*	52 WO 91/08291	13.06.91	PCT				
*	53 WO 92/20373		PCT				
*	54 WO 94/04679	03.03.94	PCT				
*	55 WO 94/04690	03.03.94	PCT				
*	56 WO 94/29348	22.12.94	PCT				
*	57 WO 95/10540	20.04.95	PCT				
*	58 WO 95/11301	27.04.95	PCT				
*	59 WO 95/31544	23.11.95	PCT				
*	60 WO 97/33904 ✓	18.09.97	PCT				
*	61 WO 97/37020	09.10.97	PCT				
*	62 WO 98/14565	09.04.98	PCT				
*	63 2,211,504	05.07.89	UNITED KINGDOM				

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

*	Adams et al., "Molecular cloning of mouse immunoglobulin heavy chain messenger ribonucleic acids coding for $\mu$ , $\alpha$ , $\gamma_1$ , $\gamma_2$ a, and $\gamma_3$ chains" <u>Biochemistry</u> 19:2711-2719 (1980)
*	Amakawa et al., "The Hodgkin Disease Antigen CD30 is Crucial for Antigen-Induced Death of Developing T Cells" <u>Symposium on Programmed Cell Death</u> (Abstract No. 10), Cold Spring Harbor Laboratory (1995)
*	Aplin and Wriston, "Preparation, Properties, and Applications of Carbohydrate Conjugates of Proteins and Lipids" <u>CRC Crit. Rev. Biochem.</u> 10(4):259-306 (1981)

Examiner	Date Considered
----------	-----------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark OfficeAtty Docket No.  
P1007R1C1Serial No.  
10/081,280

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant  
AshkenaziFiling Date  
21 Feb 2002Group  
1653

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

* 67	Ashkenazi and Chamow, "Immunoadhesins: An Alternative to Human Monoclonal Antibodies" <u>Methods: A Companion to Methods in Enzymology</u> 8:104-115 (1995)
* 68	Ashkenazi et al., "Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoadhesin" <u>Proc. Natl. Acad. Sci.</u> 88:10535-10539 (1991)
* 69	<u>Autologous Bone Marrow Transplantation: Proceedings of the Third International Symposium</u> , Dicke et al., University of Texas M.D. Anderson Hospital (1987)
* 70	Baldwin, A., "The NF-KB and IkB Proteins: New Discoveries and Insights" <u>Ann. Rev. Immunol.</u> 14:649-683 (1996)
* 71	Banerji et al., "A Lymphocyte-specific Cellular Enhancer Is Located Downstream of the Joining Region in Immunoglobulin Heavy Chain Genes" <u>Cell</u> 33:729-740 (July 1983)
* 72	Banner et al., "Crystal Structure of the Soluble Human 55 kd TNF Receptor-Human TNF $\beta$ Complex: Implications for TNF Receptor Activation" <u>Cell</u> 73:431-445 (1993)
* 73	Barr and Tomei, "Apoptosis and Its Role in Human Disease" <u>Bio/Technology</u> 12:487-493 (1994)
* 74	Bianchi et al., "Transformation of the yeast Kluyveromyces lactis by New Vectors Derived from the 1.6 $\mu$ m Circular Plasmid pKD1" <u>Curr. Genet.</u> 12:185-192 (1987)
* 75	Bodmer et al., "TRAMP, a Novel Apoptosis-Mediating Receptor with Sequence Homology to Tumor Necrosis Factor Receptor 1 and Fas(Apo-1/CD95)" <u>Immunity</u> 6:79-88 (1997)
* 76	Boerner et al., "Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes" <u>The Journal of Immunology</u> 147(1):86-95 (1991)
* 77	Boldin et al., "Involvement of MACH, a Novel MORT1/FADD-Interacting Protease, in Fas/APO-1- and TNF Receptor-Induced Cell Death" <u>Cell</u> 85:803-815 (1996)
* 78	Boldin et al., "Self-Association of the "Death Domains" of the p55 Tumor Necrosis Factor (TNF) Receptor and Fas/APO1 Prompts Signaling for TNF and Fas/APO1 Effects" <u>Journal of Biological Chemistry</u> 270:387-391 (1995)
* 79	Boulianne et al., "Production of functional chimaeric mouse/human antibody" <u>Nature</u> 312:643-646 (December 13, 1984)
* 80	Bradley, "Production and Analysis of Chimaeric Mice" <u>Teratocarcinomas and Embryonic Stem Cells: A Practical Approach</u> , E. J. Robertson, ed., IRL, Oxford, Chapter 5, pps. 113-151 (1987)
* 81	Brockhaus et al., "Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies" <u>Proc. Natl. Acad. Sci. USA</u> 87:3127-3131 (1990)
* 82	Brodeur et al., "Mouse-Human Myeloma Partners for the Production of Heterohybridomas" <u>Monoclonal Antibody Production Techniques and Applications</u> , New York:Marcel Dekker, Inc. pps. 51-63 (1987)
* 83	Brojatsch et al., "CAR1, a TNFR-Related Protein, Is a Cellular Receptor for Cytopathic Avian Leukosis-Sarcoma Viruses and Mediates Apoptosis" <u>Cell</u> 87:845-855 (1996)
* 84	Browning et al., "Lymphotoxin $\beta$ , a Novel Member of the TNF Family That Forms a Heteromeric Complex with Lymphotoxin on the Cell Surface" <u>Cell</u> 72:847-856 (1993)
* 85	Bruggemann et al., "Designer Mice: The Production of Human Antibody Repertoires in Transgenic Animals" <u>Year in Immunology</u> 7:33-40 (1993)
* 86	Burgess et al., "Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue" <u>Journal of Cell Biology</u> 111:2129-2138 (1990)

Examiner

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark OfficeAtty Docket No.  
P1007R1C1Serial No.  
10/081,280

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant  
AshkenaziFiling Date  
21 Feb 2002Group  
1653


## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

* 87	Byrn et al., "Biological Properties of a CD4 Immunoadhesin" <u>Nature</u> 344:667-670 (April 12, 1990)
* 88	Canaani et al., "Regulated Expression of Human Interferon $\beta_1$ Gene After Transduction into Cultured Mouse and Rabbit Cells" <u>Proc. Natl. Acad. Sci. USA</u> 79:5166-5170 (September 1982)
* 89	Capon et al., "Designing CD4 Immunoadhesins for AIDS Therapy" <u>Nature</u> 337:525-531 (1989)
* 90	Carter et al., "Humanization of an Anti-p185HER2 Antibody For Human Cancer Therapy" <u>Proc. Natl. Acad. Sci. USA</u> 89:4285-4289 (May 1992)
* 91	Chamow et al., "A Humanized, Bispecific Immunoadhesin-Antibody That Retargets CD3+ Effectors to Kill HIV-1-Infected Cells" <u>Journal of Immunology</u> 153:4268-4280 (1994)
* 92	Chang et al., "Phenotypic Expression in E. coli of a DNA Sequence Coding for Mouse Dihydrofolate Reductase" <u>Nature</u> 275:617-624 (October 19, 1978)
* 93	Chemotherapy Service Ed., M.C. Perry, Baltimore, MD:Williams & Wilkins (1992)
* 94	Chinnaiyan and Dixit, "The Cell-Death Machine" <u>Current Biology</u> 6:555-562 (1996)
* 95	Chinnaiyan et al., "FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis" <u>Cell</u> 81:505-512 (1995)
* 96	Chinnaiyan et al., "FADD/MORT1 Is a Common Mediator of CD95 (Fas/APO-1) and Tumor Necrosis Factor Receptor-induced Apoptosis" <u>Journal of Biological Chemistry</u> 271:4961-4965 (1996)
* 97	Chinnaiyan et al., "Signal Transduction by DR3, a Death Domain-Containing Receptor Related to TNFR-1 and CD95" <u>Science</u> 274:990-992 (1996) ✓
* 98	Chothia and Lesk, "Canonical Structures for the Hypervariable Regions of Immunoglobulins" <u>J. Mol. Biol.</u> 196:901-917 (1987)
* 99	Cleveland and Ihle, "Contenders in FasL/TNF Death Signaling" <u>Cell</u> 81:479-482 (1995)
* 100	Cohen, "Programmed Cell Death in the Immune System" <u>Advances in Immunol.</u> 50:55-85 (1991)
* 101	Cole et al., "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer" <u>Monoclonal Antibodies and Cancer Therapy</u> , New York:Alan R. Liss, Inc. pps. 77-96 (1985)
* 102	Creighton, "Protein Biosynthesis" <u>Proteins: Structures and Molecular Principles</u> , San Francisco:W.H. Freeman & Co. pps. 79-86 (1983)
* 103	Darzynkiewicz et al., "Assays of Cell Viability: Discrimination of Cells Dying by Apoptosis" <u>Methods in Cell Biol.</u> 41:15-38 (1994)
* 104	David and Reisfeld., "Protein Iodination with Solid State Lactoperoxidase." <u>Biochemistry</u> 13(5):1014-1021 (1974)
* 105	Dealtry et al., "DNA Fragmentation and Cytotoxicity Caused by Tumor Necrosis Factor is Enhanced by Interferon- $\gamma$ " <u>European Journal of Immunology</u> 17:689-693 (1987)
* 106	deBoer et al., "The TAC Promoter: A functional Hybrid Derived From the TRP and LAC Promoters" <u>Proc. Natl. Acad. Sci. USA</u> 80:21-25 (1983)

Examiner

Date Considered

\* Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark OfficeAtty Docket No.  
P1007R1C1Serial No.  
10/081,280

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant  
AshkenaziFiling Date  
21 Feb 2002Group  
1653

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

*107	Degli-Esposti et al., "Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family" <u>Journal of Experimental Medicine</u> 186(7):1165-1170 (1997)
*108	Depicker et al., "Nopaline Synthase: Transcript Mapping and DNA Sequence" <u>J. Mol. Appl. Gen.</u> 1:561-573 (1982)
*109	Depicker et al., "Nopaline Synthase: Transcript Mapping and DNA Sequence" <u>J. Molecular and Applied Genetics</u> 1(6):561-573 (1982)
*110	Dieffenbach et al., <u>PCR Primer: A Laboratory Manual</u> , Cold Spring Harbor Laboratory Press pps. 1:16;133-142 (1995)
*111	Dolby et al., "Cloning and partial nucleotide sequence of human immunoglobulin μ chain cDNA from B cells and mouse-human hybridomas" <u>Proc. Natl. Acad. Sci. USA</u> 77(10):6027-6031 (1980)
*112	Duksin et al., "Relationship of the Structure and Biological Activity of the Natural Homologues of Tunicamycin" <u>Journal of Biological Chemistry</u> 257:3105-3109 (1982)
*113	Eck and Sprang, "The structure of tumor necrosis factor-α at 2.6 Å resolution" <u>Journal of Biological Chemistry</u> 264(29):17595-17605 (1989)
*114	Eck et al., "The Structure of Human Lymphotoxin (Tumor Necrosis Factor-β) at 1.9-Å Resolution" <u>J. Bio. Chem.</u> 267:2119-2122 (1992)
*115	Edge et al., "Deglycosylation of glycoproteins by trifluoromethanesulfonic acid" <u>Analytical Biochemistry</u> 118:131-137 (1981)
*116	Enari et al., "Involvement of an ICE-like protease in Fas-mediated Apoptosis" <u>Nature</u> 375:78-81 (1995)
*117	Evan et al., "Isolation of Monoclonal Antibodies Specific for Human c-myc Proto-Oncogene Product" <u>Molecular &amp; Cellular Biology</u> 5:3610-3616 (1985)
*118	Fadok et al., "Exposure of Phosphatidylserine on the Surface of Apoptotic Lymphocytes Triggers Specific Recognition and Removal by Macrophages" <u>J. Immunol.</u> 148:2207-2216 (1992)
*119	Falkner and Zachau, "Expression of mouse immunoglobulin genes in monkey cells" <u>Nature</u> 298:286-288 (1982)
*120	Field et al., "Purification of a RAS-Responsive Adenylyl Cyclase Complex from <i>Saccharomyces cerevisiae</i> by Use of an Epitope Addition Method" <u>Molecular &amp; Cellular Biology</u> 8:2159-2165 (1988)
*121	Fiers et al., "Complete Nucleotide Sequence of SV40 DNA" <u>Nature</u> 273:113-120 (May 11, 1978)
*122	Fleer et al., "Stable Multicopy Vectors for High-Level Secretion of Recombinant Human Serum Albumin by <i>Kluyveromyces Yeasts</i> " <u>Bio/Technology</u> 9:968-975 (1991)
*123	Fraser and Evan, "A License to Kill" <u>Cell</u> 85:781-784 (1996)
*124	Gething and Sambrook, "Cell-surface Expression of Influenza Haemagglutinin from a Cloned DNA Copy of the RNA Gene" <u>Nature</u> 293:620-625 (October 22, 1981)
*125	Goding, "Production of Monoclonal Antibodies" <u>Monoclonal Antibodies: Principles and Practice</u> , Academic Press, pps. 59-103 (1986)
*126	Goeddel et al., "Direct Expression in <i>Escherichia coli</i> of a DNA Sequence Coding for Human Growth Hormone" <u>Nature</u> 281:544-548 (October 18, 1979)

Examiner

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark OfficeAtty Docket No.  
P1007R1C1Serial No.  
10/081,280

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant  
AshkenaziFiling Date  
21 Feb 2002Group  
1653

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

*127	Goeddel et al., "Synthesis of Human Fibroblast Interferon by E. coli" <u>Nucleic Acids Research</u> 8(18):4057-4074 (1980)
*128	Goodwin et al., "Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor" <u>Molecular &amp; Cellular Biology</u> 11:3020-3026 (1991)
*129	Gorman et al., "The Rous Sarcoma Virus Long Terminal Repeat is a Strong Promoter When Introduced into a Variety of Eukaryotic Cells by DNA-Mediated Transfection" <u>Proc. Natl. Acad. Sci. USA</u> 79:6777-6781 (November 1982)
*130	Gough et al., "Molecular cloning of seven mouse immunoglobulin κ chain messenger ribonucleic acids" <u>Biochemistry</u> 19:2702-2710 (1980)
*131	Graham and van der Eb, "A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA" <u>Virology</u> 52:456-467 (1973)
*132	Graham et al., "Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5" <u>J. Gen. Virol.</u> 36:59-72 (1977)
*133	Gray et al., "Expression of Human Immune Interferon cDNA in E. coli and Monkey Cells" <u>Nature</u> 295:503-508 (February 11, 1982)
*134	Greenaway et al., "Human Cytomegalovirus DNA: BamHI, EcoRI and PstI Restriction Endonuclease Cleavage Maps" <u>Gene</u> 18:355-360 (1982)
*135	Grenet et al., "Duplication of the DR3 Gene on Human Chromosome 1p36 and Its Deletion in Human Neuroblastoma" <u>Genomics</u> 49:385-393 (1998)
*136	Gruss and Dower, "Tumor Necrosis Factor Ligand Superfamily: Involvement in the Pathology of Malignant Lymphomas" <u>Blood</u> 85:3378-3404 (1995)
*137	Hale et al., "Demonstration of in vitro and in vivo efficacy of two biologically active human soluble TNF receptors expressed in E. coli" <u>J. Cell. Biochem.</u> (abstract only Supplement 15F; P 424) pps. 113 (1991)
138	Harlow et al. <u>Antibodies: A Laboratory Manual</u> , Cold Spring Harbor Laboratory, Chapter 5, pps. 72-77, 92-97, 128-135, 141-157 (1988)
*139	Hess et al., "Cooperation of Glycolytic Enzymes" <u>Advances in Enzyme Regulation</u> , George Weber, New York:Pergamon Press Vol. 7:149-167 (1968)
*140	Hillier et al. (Genbank Accession No. H-41522) (July 31, 1995)
*141	Hitzeman et al., "Isolation and Characterization of the Yeast 3-Phosphoglycerokinase Gene (PGK) by an Immunological Screening Technique" <u>Journal of Biological Chemistry</u> 255(24):12073-12080 (December 25, 1980)
*142	Hohmann et al., "Two different cell types have different major receptors for human tumor necrosis factor (TNFα)" <u>Journal of Biological Chemistry</u> 264(25):14927-14934 (1989)
*143	Holland and Holland, "Isolation and Identification of Yeast Messenger Ribonucleic Acids Coding for Enolase, Glyceraldehyde-3-phosphate Dehydrogenase, and Phosphoglycerate Kinase" <u>Biochemistry</u> 17(23):4900-4907 (1978)
*144	Hoogenboom and Winter, "By-Passing Immunisation: Human Antibodies from Synthetic Repertoires of Germline V <sub>H</sub> Gene Segments Rearranged in Vitro" <u>J. Mol. Biol.</u> 227:381-388 (1992)
*145	Hopp et al., "A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification" <u>Bio/Technology</u> 6:1204-1210 (1988)
*146	Hsiao and Carbon, "High-frequency Transformation of Yeast by Plasmids Containing the Cloned Yeast Arg <sup>4</sup> Gene" <u>Proc. Natl. Acad. Sci. USA</u> 76:3829-3833 (1979)

Examiner

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1007R1C1	Serial No. 10/081,280
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)			Applicant Ashkenazi	
			Filing Date 21 Feb 2002	Group 1653
<b>OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)</b>				
*147	Hsu et al., "TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways" <u>Cell</u> 84:299-308 (1996)			
*148	Hunter et al., "Preparation of Iodine 131 Labelled Human Growth Hormone of High Specific Activity" <u>Nature</u> 194:495-496 (1962)			
*149	Itoh et al., "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis" <u>Cell</u> 66:233-243 (1991)			
*150	Jakobovits et al., "Analysis of Homozygous Mutant Chimeric Mice: Deletion of the Immunoglobulin Heavy-Chain Joining Region Blocks B-cell Development and Antibody Production" <u>Proc. Natl. Acad. Sci. USA</u> 90:2551-2555 (March 1993)			
*151	Jakobovits et al., "Germ-line Transmission and Expression of a Human-Derived Yeast Artificial Chromosome" <u>Nature</u> 362:255-258 (March 18, 1993)			
*152	Johnson et al., "Expression and Structure of the Human NGF Receptor" <u>Cell</u> 47:545-554 (1986)			
*153	Jones et al., "Replacing the Complementarity-Determining Regions in a Human Antibody with those from a Mouse" <u>Nature</u> 321:522-525 (May 29, 1986)			
*154	Jones, E., "Proteinase Mutants of <i>Saccharomyces Cerevisiae</i> " <u>Genetics</u> 85(1):23-33 (1977)			
*155	Karin, "The Regulation of AP-1 Activity by Mitogen-activated Protein Kinases" <u>Journal of Biological Chemistry</u> 270:16483-16486 (1995)			
*156	Keown et al., "Methods for Introducing DNA into Mammalian Cells" <u>Methods in Enzymology</u> 185:527-537 (1990)			
*157	Kingsman et al., "Replication in <i>Saccharomyces Cerevisiae</i> of Plasmid pBR313 Carrying DNA from the Yeast trpl Region" <u>Gene</u> 7:141-152 (1979)			
*158	Kitson et al., "A Death-Domain-Containing Receptor that Mediates Apoptosis" <u>Nature</u> 384:372-375 (1996)			
*159	Kohler, G. and Milstein, C., "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity" <u>Nature</u> 256:495-497 (August 7, 1975)			
*160	Kohno et al., "A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor" <u>Proc. Natl. Acad. Sci. USA</u> 87:8331-8335 (1990)			
*161	Koopman et al., "Annexin V for Flow Cytometric Detection of Phosphatidylserine Expression on B Cells Undergoing Apoptosis" <u>Blood</u> 84:1415-1420 (1994)			
*162	Kozak, "An analysis of vertebrate mRNA sequences: intimations of translational control" <u>Journal of Cell Biology</u> 115:887-903 (1991)			
*163	Kozbor et al., "A Human Hybrid Myeloma for Production of Human Monoclonal Antibodies" <u>The Journal of Immunology</u> 133(6):3001-3005 (1984)			
*164	Krammer et al., "Regulation of Apoptosis in the Immune System" <u>Curr. Op. Immunol.</u> 6:279-289 (1994)			
*165	Kyriakis et al., "Sounding the Alarm: Protein Kinase Cascades Activated by Stress and Inflammation" <u>Journal of Biological Chemistry</u> 271:24313-24316 (1996)			
*166	Laimins et al., "Osmotic Control of kdp Operon Expression in <i>Escherichia Coli</i> " <u>Proc. Natl. Acad. Sci. USA</u> 78(1):464-468 (Jan 1981)			
Examiner		Date Considered		
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>				



FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark OfficeAtty Docket No.  
P1007R1C1Serial No.  
10/081,280

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant  
AshkenaziFiling Date  
21 Feb 2002Group  
1653

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

*167	Lasky et al., "DNA sequence analysis of the type-common glycoprotein-D genes of herpes simplex virus types 1 and 2" <u>DNA</u> 3(1):23-29 (1984)
*168	Lasky et al., "Neutralization of the AIDS Retrovirus by Antibodies to a Recombinant Envelope Glycoprotein" <u>Science</u> 233:209-212 (1986)
*169	Lazar et al., "Transforming Growth Factor $\alpha$ : Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities" <u>Molecular &amp; Cellular Biology</u> 8(3):1247-1252 (Mar. 1988)
*170	Lenardo, "Interleukin-2 Programs Mouse $\alpha\beta$ T Lymphocytes for Apoptosis" <u>Nature</u> 353:858-861 (1991)
*171	Lesslauer et al., "Bioactivity of recombinant human TNF receptor fragments" <u>J. Cell. Biochem.</u> (abstract only, Supplement 15F; P432) p. 115 (1991)
*172	Lewis et al., "Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific" <u>Proc. Natl. Acad. Sci. USA</u> 88:2830-2834 (1991)
*173	Li et al., "Targeted Mutation of the DNA Methyltransferase Gene Results in Embryonic Lethality." <u>Cell.</u> 69:915-926 (Jun 1992)
*174	Liu et al., "Dissection of TNF Receptor 1 Effector Functions: JNK Activation is not Linked to Apoptosis While NF- $\kappa$ B Activation Prevents Cell Death" <u>Cell</u> 87:565-576 (1996)
*175	Loetscher et al., "Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor" <u>Cell</u> 61:351-359 (1990)
*176	Luckow et al., "Trends in the Development of Baculovirus Expression Vectors" <u>Bio/Technology</u> 6:47-55 (1988)
*177	Lusky et al., "Bovine Papilloma Virus Contains an Activator of Gene Expression at the Distal End of the Early Transcription Unit" <u>Molecular &amp; Cellular Biology</u> 3(6):1108-1122 (June 1983)
*178	Lutz-Freyermuth et al., "Quantitative Determination That One of Two Potential RNA-binding Domains of the A Protein Component of the U1 Small Nuclear Ribonucleoprotein Complex Binds with High Affinity to Stem-loop II of U1 RNA" <u>Proc. Natl. Acad. Sci. USA</u> 87:6393-6397 (1990)
*179	MacFarlane et al., "Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL" <u>Journal of Biological Chemistry</u> 272(41):25417-25420 (1997)
*180	MacKay et al., "Differential Responses of Fibroblasts from Wild-Type and TNF-R55-Deficient Mice to Mouse and Human TNF- $\alpha$ Activation" <u>J. Immunol.</u> 153:5274-5284 (1994)
*181	Maeda et al., "Production of Human $\alpha$ -interferon in Silkworm Using a Baculovirus Vector" <u>Nature</u> 315:592-594 (June 13, 1985)
*182	Mage et al., "Preparation of Fab and F(ab') <sub>2</sub> Fragments from Monoclonal Antibodies" <u>Monoclonal Antibody Production Techniques and Applications</u> , New York:Marcel Dekker, Inc. pps. 79-97 (1987)
*183	Mallett et al., "Characterization of the MRC OX40 Antigen of Activated CD4 Positive T Lymphocytes - a Molecule Related to Nerve Growth Factor Receptor" <u>EMBO Journal</u> 9:1063-1068 (1990)
*184	Mammalian Cell Biotechnology: A Practical Approach, M. Butler, ed., IRL Press (1991)
*185	Mansour et al., "Disruption of the Proto-oncogene int-2 in Mouse Embryo-derived Stem Cells: a General Strategy for Targeting Mutations to Non-selectable Genes" <u>Nature</u> 336:348-352 (1988)
*186	Mantel et al., "Rabbit $\beta$ -globin mRNA Production in Mouse L Cells Transformed with Cloned Rabbit $\beta$ -globin Chromosomal DNA" <u>Nature</u> 281:40-46 (September 6, 1979)

Examiner

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark OfficeAtty Docket No.  
P1007R1C1Serial No.  
10/081,280

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant  
AshkenaziFiling Date  
21 Feb 2002Group  
1653

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

*187	Marks et al., "By-Passing Immunization: Human Antibodies From V-gene Libraries Displayed On Phage." <u>J. Mol. Biol.</u> 222:581-597 (1991)
*188	Marsters et al., "Apo-3, a New Member of the Tumor Necrosis Factor Receptor Family, Contains a Death Domain and Activates Apoptosis and NF- $\kappa$ B" <u>Curr. Biol.</u> 6(12):1669-1676 (1996)
*189	Marsters et al., "Interferon $\gamma$ Signals Via a High-Affinity Multisubunit Receptor Complex That Contains Two Types of Polypeptide Chain" <u>Proc. Natl. Acad. Sci. USA</u> 92:5401-5405 (1995)
*190	Martin et al., "Cell-free Reconstitution of Fas-, UV Radiation- and Ceramide-induced Apoptosis" <u>EMBO Journal</u> 14(21):5191-5200 (1995)
*191	Martin et al., "GAP Domains Responsible for Ras p21-Dependent Inhibition of Muscarinic Atrial K <sup>+</sup> Channel Currents" <u>Science</u> 255:192-194 (1992)
*192	Mather et al., "Culture of Testicular Cells in Hormone-Supplemented Serum-Free Medium" <u>Annals N.Y. Acad. Sci.</u> 383:44-68 (1982)
*193	Mather, J.P., "Establishment and Characterization of Two Distinct Mouse Testicular Epithelial Cell Lines" <u>Biol. Reprod.</u> 23:243-252 (1980)
*194	Maxam et al., "Sequencing End-labeled DNA with Base-Specific Chemical Cleavages" <u>Methods in Enzymology</u> 65:499-560 (1980)
*195	McCafferty et al., "Phage antibodies: filamentous phage displaying antibody variable domains" <u>Nature</u> 348:552-554 (1990)
*196	Messing et al., "A System for Shotgun DNA Sequencing" <u>Nucleic Acids Research</u> 9(2):309-321 (1981)
*197	Miller et al., "An Insect Baculovirus Host-Vector System for High-Level Expression of Foreign Genes" <u>Genetic Engineering</u> , Setlow et al., Plenum Publishing Vol. 8:277-298 (1986)
*198	Milstein and Cuello, "Hybrid Hybridomas and Their Use in Immunohistochemistry" <u>Nature</u> 305:537-540 (Oct 1983)
*199	Montgomery et al., "Herpes Simplex Virus-1 Entry into Cells Mediated by a Novel Member of the TNF/NGF Receptor Family" <u>Cell</u> 87(3):427-436 (1996)
*200	Moore et al., "Apoptosis in CHO Cell Batch Cultures: Examination by Flow Cytometry" <u>Cytotechnology</u> 17:1-11 (1995)
*201	Mordenti et al., "Interspecies Scaling of Clearance and Volume of Distribution Data for Five Therapeutic Proteins" <u>Pharmaceutical Research</u> 8(11):1351-1359 (1991)
*202	Morrison et al., "Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains with Human Constant Region Domains." <u>Proc. Natl. Acad. Sci. USA</u> 81:6851-6855 (November 1984)
*203	Morrison et al., "Transfer and expression of immunoglobulin genes" <u>Annual Review of Immunology</u> 2:239-256 (1984)
*204	Morrison, S. L., "Transfectomas Provide Novel Chimeric Antibodies" <u>Science</u> 229:1202-1207 (September 20, 1985)
*205	Mulligan et al., "Expression of a Bacterial Gene in Mammalian Cells" <u>Science</u> 209:1422-1427 (Sep 1980)
*206	Munro, "Uses of chimaeric antibodies" <u>Nature</u> 312:597 (1984)

Examiner

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

JAN 17 2006

Sheet 10 of 15

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1007R1C1	Serial No. 10/081,280
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		Applicant Ashkenazi		
		Filing Date 21 Feb 2002	Group 1653	
<b>OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)</b>				
*207	Munson and Rodbard, "LIGAND: A Versatile Computerized Approach for Characterization of Ligand-Binding Systems" <u>Analytical Biochemistry</u> 107:220-239 (1980)			
*208	Muzio et al., "FLICE, A Novel FADD-Homologous ICE/CED-3-like Protease, Is Recruited to the CD95 (Fas/APO-1) Death-Inducing Signaling Complex" <u>Cell</u> 85:817-827 (1996)			
*209	Nagata and Golstein, "The Fas Death Factor" <u>Science</u> 267:1449-1456 (1995)			
*210	NCBI/Genbank EST; Locus H19739: (computer printout attached)			
*211	NCBI/Genbank EST; Locus H22502: (computer printout attached)			
*212	NCBI/Genbank EST; Locus H41522: (computer printout attached)			
*213	NCBI/Genbank EST; Locus H41851: (computer printout attached)			
*214	NCBI/GenBank EST; Locus H43566: (computer printout attached)			
*215	NCBI/GenBank EST; Locus H44565: (computer printout attached)			
*216	NCBI/GenBank EST; Locus H44567: (computer printout attached)			
*217	NCBI/GenBank EST; Locus H44772: (computer printout attached)			
*218	NCBI/Genbank EST; Locus H46211: (computer printout attached)			
*219	NCBI/Genbank EST; Locus H46378: (computer printout attached)			
*220	NCBI/Genbank EST; Locus H46424: (Computer printout attached)			
*221	NCBI/Genbank EST; Locus H46662: (computer printout attached)			
*222	NCBI/Genbank EST; Locus H49675: (computer printout attached)			
*223	NCBI/GenBank EST; Locus H54628: (computer printout attached)			
*224	NCBI/GenBank EST; Locus H54629: (computer printout attached)			
*225	NCBI/GenBank EST; Locus HHEA47M: (computer printout attached)			
*226	NCBI/GenBank EST; Locus R31020: (computer printout attached)			
Examiner		Date Considered		
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>				



FORM PTO-1449	U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1007R1C1	Serial No. 10/081, 280
		Applicant Ashkenazi	
		Filing Date 21 Feb 2002	Group 1653
<b>OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)</b>			
*227	NCBI/GenBank EST; Locus T10524: (computer printout attached)		
*228	NCBI/GenBank EST; Locus T82085: (computer printout attached)		
*229	NCBI/GenBank EST; Locus T90422: (computer printout attached)		
*230	NCBI/Genbank EST; Locus W01590: (computer printout attached)		
*231	NCBI/Genbank EST; Locus W01592: (computer printout attached)		
*232	NCBI/Genbank EST; Locus W71984: (computer printout attached)		
*233	NCBI/Genbank; EST Locus H46374: (computer printout attached)		
*234	Neuberger et al., "Recombinant Antibodies Possessing Novel Effector Functions" <u>Nature</u> 312:604-608 (December 13, 1984)		
*235	New England Biolabs, Catalog pps. 60-62		
*236	Nophar et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor" <u>EMBO Journal</u> 9:3269-3278 (1990)		
*237	Nygren, H., "Conjugation of Horseradish Peroxidase to Fab Fragments with Different Homobifunctional and Heterobifunctional Cross-Linking Reagents" <u>The Journal of Histochemistry and Cytochemistry</u> 30(5):407-412 (1982)		
*238	O'Reilley et al. <u>Baculovirus Expression Vectors: A Laboratory Manual</u> , Oxford:Oxford University Press (1994)		
*239	Osborne et al., "Transcription Control Region Within the Protein-coding Portion of Adenovirus E1A Genes" <u>Molecular &amp; Cellular Biology</u> 4(7):1293-1305 (July 1984)		
*240	Paborsky et al., "Mammalian Cell Transient Expression of Tissue Factor for the Production of Antigen" <u>Protein Eng.</u> 3(6):547-553 (1990)		
*241	Pain et al., "Preparation of Protein A-Peroxidase Monoconjugate Using a Heterobifunctional Reagent, and its Use in Enzyme Immunoassays" <u>Journal of Immunological Methods</u> 40:219-230 (1981)		
*242	Pati, U., "Novel vectors for expression of cDNA encoding epitope-tagged proteins in mammalian cells" <u>Gene</u> 114:285-288 (1992)		
*243	Pavlakis et al., "Expression of Two Human Growth Hormone Genes in Monkey Cells Infected by Simian Virus 40 Recombinants" <u>Proc. Natl. Acad. Sci. USA</u> 78(12):7398-7402 (December 1981)		
*244	Peetre et al., "A tumor necrosis factor binding protein is present in human biological fluids" <u>European Journal of Haematology</u> 41:414-419 (1988)		
*245	Pennica et al., "Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy" <u>Proc. Natl. Acad. Sci. USA</u> 92:1142-1146 (1995)		
*246	Pennica et al., "Human Tumour Necrosis Factor: Precursor Structure, Expression and Homology to Lymphotoxin" <u>Nature</u> 312:724-729 (1984)		
Examiner		Date Considered	
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			



FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark OfficeAtty Docket No.  
P1007R1C1Serial No.  
10/081,280

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant  
AshkenaziFiling Date  
21 Feb 2002Group  
1653

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

*247	Peppel and Beutler, "Chimaeric TNF-Receptor-IgG Molecule Acts as Soluble Inhibitor of TNF Mediated Cytotoxicity" <u>J. Cell. Biochem.</u> (abstract only, Supplement 15F; P439) p. 118 (1991)
*248	Pitti et al., "Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family" <u>Journal of Biological Chemistry</u> 271:12687-12690 (1996)
*249	Presta et al., "Humanization of an Antibody Directed Against IgE" <u>J. Immunol.</u> 151(5):2623-2632 (September 1, 1993)
*250	Presta, L., "Antibody Engineering" <u>Curr. Op. Struct. Biol.</u> 2:593-596 (1992)
*251	Public Databases, "MP Search output from Public Databases EST-SIS and EST-SIS-TWO for accession numbers H46211; J46378; H46374; H41851; and H49675" (July 31, 1995)
*252	Queen et al., "A humanized antibody that binds to the interleukin 2 receptor" <u>Proc. Natl. Acad. Sci. USA</u> 86(24):10029-10033 (December 1989)
*253	Radeke et al., "Gene transfer and molecular cloning of the rat nerve growth factor receptor" <u>Nature</u> 325:593-597 (1987)
*254	Raff, "Social Controls on Cell Survival and Cell Death" <u>Nature</u> 356:397-400 (1992)
*255	Raven et al., "Cloning and Functional Analysis of a Novel Protein Which Binds To The p55 TNF Receptor Death Domain" <u>Euro. Cytokine Network</u> (abstract No. 82) 7:210 (April-Jun 1996)
*256	Raven et al., "Cloning and Functional Analysis of a Novel Protein Which Binds to the p55 TNF Receptor Death Domain" <u>Programmed Cell Death Meeting</u> (abstract only) pps. 127 (20-24 September 1995)
*257	Ray et al., "Viral Inhibition of Inflammation: Cowpox Virus Encodes an Inhibitor of the Interleukin-1 $\beta$ Converting Enzyme" <u>Cell</u> 69:597-604 (May 15, 1992)
*258	Remington's Pharmaceutical Sciences, Oslo et al., eds., 16th edition, Mack Publishing Co. (1980)
*259	Reyes et al., "Expression of Human $\beta$ -interferon cDNA Under the Control of a Thymidine Kinase Promoter from Herpes Simplex Virus" <u>Nature</u> 297:598-601 (June 17, 1982)
*260	Rice and Baltimore, "Regulated expression of an immunoglobulin $\kappa$ gene introduced into a mouse lymphoid cell line" <u>Proc. Natl. Acad. Sci. USA</u> 79:7862-7865 (1982)
*261	Riechmann et al., "Reshaping Human Antibodies for Therapy" <u>Nature</u> 332:323-327 (Mar 24, 1988)
*262	Rothe et al., "A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor" <u>Cell</u> 78:681-692 (1994)
*263	Rudinger, J., "Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence" <u>Peptide Hormones</u> , J.A. Parsons, Baltimore:University Park Press pps. 1-7 (1976)
*264	Ruppert et al., "Cloning and Expression of Human TAFII250: a TBP-associated Factor Implicated in Cell-cycle Regulation" <u>Nature</u> 362:175-179 (1993)
*265	Sachs et al., "Control of Programmed Cell Death in Normal and Leukemic Cells: New Implications for Therapy" <u>Blood</u> 82:15-21 (1993)
*266	Sambrook et al. <u>Molecular Cloning: A Laboratory Manual</u> , Second edition, New York:Cold Spring Harbor Laboratory Press (1989)

Examiner

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark OfficeAtty Docket No.  
P1007R1C1Serial No.  
10/081,280

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant  
AshkenaziFiling Date  
21 Feb 2002Group  
1653

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

*267	Sambrook et al., "Molecular cloning a Laboratory Manual", Cold Spring Harbor Laboratory Press pps. 16.1-17.4L (1989)
*268	Schall et al., "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor" <u>Cell</u> 61:361-370 (1990)
*269	Schmid et al., "DNA Fragmentation: Manifestation of Target Cell Destruction Mediated by Cytotoxic T-cell Lines, Lymphotoxin-secreting Helper T-cell Clones, and Cell-free Lymphotoxin-containing Supernatant" <u>Proc. Natl. Acad. Sci. USA</u> 83:1881-1885 (1986)
*270	Screaton et al., "LARD: A new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing" <u>Proc. Natl. Acad. Sci.</u> 94:4615-4619 (1997)
*271	Seckinger et al., "Purification and biologic characterization of a specific tumor necrosis factor α Inhibitor" <u>Journal of Biological Chemistry</u> 264:11966-11973 (1989)
*272	Sharon et al., "Expression of a V <sub>H</sub> C <sub>k</sub> chimaeric protein in mouse myeloma cells" <u>Nature</u> 309:364-367 (1984)
*273	Shaw et al., "A General Method for the Transfer of Cloned Genes to Plant Cells" <u>Gene</u> 23:315-330 (1983)
*274	Siebenlist et al., "E. Coli RNA Polymerase Interacts Homologously with Two Different Promoters" <u>Cell</u> 20:269-281 (June 1980)
*275	Simonet et al., "Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density" <u>Cell</u> 89:309-319 (1997)
*276	Sims et al., "A Humanized CD18 Antibody Can Block Function Without Cell Destruction" <u>The Journal of Immunology</u> 151(4):2296-2308 (Aug 1993)
*277	Skinner et al., "Use of the Glu-Glu-Phe C-Terminal Epitope for Rapid Purification of the Catalytic Domain of Normal and Mutant ras GTPase-activating Proteins." <u>J. Bio. Chem.</u> 266:14163-14166 (1991)
*278	Smith et al., "A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins" <u>Science</u> 248:1019-1023 (1990)
*279	Smith et al., "Structure and Activity Dependence of Recombinant Human Insulin-Like Growth Factor II on Disulfide Bond Pairing" <u>Journal of Biological Chemistry</u> 264(16):9314-9321 (1989)
*280	Smith et al., "T2 Open reading frame from the shope fibroma virus encodes a soluble form of the TNF receptor" <u>Biochem. &amp; Biophys. Res. Comm.</u> 176:335-342 (1991)
*281	Sojar et al., "A Chemical Method for the Deglycosylation of Proteins" <u>Archives of Biochemistry &amp; Biophysics</u> 259(1):52-57 (1987)
*282	Southern et al., "Transformation of Mammalian Cells to Antibiotic Resistance with a Bacterial Gene Under Control of the SV40 Early Region Promoter" <u>J. Molec. Appl. Genet.</u> 1:327-341 (1982)
*283	Stamenkovic et al., "A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas" <u>EMBO Journal</u> 8(5):1403-1410 (1989)
284	Stecher et al., "The MERCK INDEX" NJ: Merck & Co, Inc, Eighth edition:page 497 (1968)
*285	Steller, H., "Mechanisms and Genes of Cellular Suicide" <u>Science</u> 267:1445-1449 (1995)
*286	Stinchcomb et al., "Isolation and Characterisation of a Yeast Chromosomal Replicator" <u>Nature</u> 282:39-43 (November 1, 1979)

Examiner

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449	U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1007R1C1	Serial No. 10/081,280
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		Applicant Ashkenazi	
		Filing Date 21 Feb 2002	Group 1653

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

*287	Suda et al., "Molecular Cloning and Expression of the Fas Ligand, a Novel Member of the Tumor Necrosis Factor Family" <u>Cell</u> 75:1169-1178 (1993)
*288	Sudgen et al., "A Vector That Replicates as a Plasmid and Can Be Efficiently Selected in B-Lymphoblasts Transformed by Epstein-Barr Virus" <u>Molecular &amp; Cellular Biology</u> 5(2):410-413 (February 1985)
*289	Sugden et al., "A Vector that Replicates as a Plasmid and Can Be Efficiently Selected in B-Lymphoblasts Transformed by Epstein-Barr Virus" <u>Molecular &amp; Cellular Biology</u> 5:410-413 (1985)
*290	Suresh et al., "Bispecific Monoclonal Antibodies from Hybrid Hybridomas" <u>Methods in Enzymology</u> 121:210-228 (1986)
*291	Suva et al., "A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression" <u>Science</u> 237(4817):893-896 (Aug. 1987)
*292	Takao et al., "Novel DNA Polymorphism in the Mouse Tumor Necrosis Factor Receptors Type 1 and Type 2" <u>Immunogenetics</u> 37:199-203 (1993)
*293	Tan et al., "Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells" <u>Gene</u> 204:35-46 (Dec 19, 1997)
*294	Tartaglia and Goeddel, "Tumor necrosis factor receptor signaling. A dominant negative mutation suppresses the activation of the 55-kDa tumor necrosis factor receptor" <u>Journal of Biological Chemistry</u> 267(7):4304-4307 (1992)
*295	Tartaglia et al., "A novel domain within the 55 kd TNF receptor signals cell death" <u>Cell</u> 74(5):845-853 (1993)
*296	Tewari and Dixit, "Fas- and Tumor Necrosis Factor-induced Apoptosis Is Inhibited by the Poxvirus crmA Gene Product" <u>Journal of Biological Chemistry</u> 270:3255-3260 (1995)
*297	Tewari and Dixit, "Recent Advances in Tumor Necrosis Factor and CD40 Signaling" <u>Curr. Op. Genet. Develop.</u> 6:39-44 (1996)
*298	Tewari et al., "Yama/CPP32 $\beta$ , a Mammalian Homolog of CED-3, Is a CrmA-Inhibitable Protease That Cleaves the Death Substrate Poly(ADP-Ribose) Polymerase" <u>Cell</u> 81:801-809 (1995)
*299	Thomas and Capecchi, "Site-Directed Mutagenesis by Gene Targeting in Mouse Embryo-Derived Stem Cells." <u>Cell</u> 51:503-512 (Nov 1987)
*300	Thomas, P., "Hybridization of Denatured RNA and Small DNA Fragments Transferred to Nitrocellulose" <u>Proc. Natl. Acad. Sci. USA</u> 77(9):5201-5205 (September 1980)
*301	Thompson, "Apoptosis in the Pathogenesis and Treatment of Disease" <u>Science</u> 267:1456-1462 (1995)
*302	Thotakura and Bahl, "Enzymatic Deglycosylation of Glycoproteins" <u>Meth. Enzymol.</u> 138:350-359 (1987)
*303	Tissue Culture, Kruse and Patterson, eds., New York:Academic Press (1973)
*304	Traunecker et al., "Bispecific Single Chain Molecules (Janusins) Target Cytotoxic Lymphocytes on HIV Infected Cells" <u>EMBO Journal</u> 10(12):3655-3659 (1991)
*305	Traunecker et al., "Highly Efficient Neutralization of HIV with Recombinant CD4-immunoglobulin Molecules" <u>Nature</u> 339:68-70 (1989)
*306	Tschumper and Carbon, "Sequence of a Yeast DNA Fragment Containing a Chromosomal Replicator and the TRP1 Gene" <u>Gene</u> 10:157-166 (1980)

Examiner	Date Considered
----------	-----------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449	U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1007R1C1	Serial No. 10/081,280
		Applicant Ashkenazi	
		Filing Date 21 Feb 2002	Group 1653

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

*307	Upton et al., "Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence" <u>Virology</u> 184:370-382 (1991)
*308	Upton et al., "Tumorigenic poxviruses: genomic organization and DNA sequence of the telomeric region of the shope fibroma virus genome" <u>Virology</u> 160:20-30 (1987)
*309	Urlaub and Chasin, "Isolation of Chinese Hamster Cell Mutants Deficient in Dihydrofolate Reductase Activity" <u>Proc. Natl. Acad. Sci. USA</u> 77(7):4216-4220 (July 1980)
*310	Van den Berg et al., "Kluyveromyces as a Host for Heterologous Gene Expression: Expression and Secretion of Prochymosin" <u>Bio/Technology</u> 8:135-139 (1990)
*311	Van Solingen et al., "Fusion of Yeast Spheroplasts" <u>J. Bact.</u> 130:946-947 (1977)
*312	Verhoeven, M. et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity" <u>Science</u> 239:1534-1536 (Mar 25, 1988)
*313	Verma et al., "Rel/NF-KB/IkB Family: Intimate Tales of Association and Dissociation" <u>Genes Develop.</u> 9:2723-2735 (1995)
*314	von Bulow and Bram, "NF-AT Activation Induced by a CAML-Interacting Member of the Tumor Necrosis Factor Receptor Superfamily" <u>Science</u> 278:138-141 (1997)
*315	Walczak et al., "TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL" <u>EMBO Journal</u> 16(17):5386-5397 (1997)
*316	Warzocha et al., "A New Death Receptor 3 Isoform: Expression in Human Lymphoid Cell Lines and Non-Hodgkin's Lymphomas" <u>Biochemical and Biophysical Research Communications</u> 242:376-379 (1998)
*317	Watanabe-Fukunaga et al., "Lymphoproliferation Disorder in Mice Explained by Defects in Fas Antigen that Mediates Apoptosis" <u>Nature</u> 356:314-317 (1992)
*318	Welcher et al., "Nerve growth factor binding domain of the nerve growth factor receptor" <u>Proc. Natl. Acad. Sci. USA</u> 88:159-163 (1991)
*319	Wiley et al., "Identification and Characterization of a New Member of the TNF Family that Induces Apoptosis" <u>Immunity</u> 3:673-682 (1995)
*320	Wong et al., "TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells" <u>Journal of Biological Chemistry</u> 272(40):25190-25194 (Oct 3, 1997)
*321	Yan and Chao, "Disruption of Cysteine-rich repeats of the p75 nerve growth factor receptor leads to loss of ligand binding" <u>Journal of Biological Chemistry</u> 266:12099-12104 (1991)
*322	Yaniv, M., "Enhancing Elements for Activation of Eukaryotic Promoters" <u>Nature</u> 297(6):17-18 (May 1982)
*323	Yonehara et al., "A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor" <u>Journal of Experimental Medicine</u> 169:1747-1756 (1989)
*324	Zheng et al., "Induction of Apoptosis in Mature T Cells by Tumor Necrosis Factor" <u>Nature</u> 377:348-351 (1995)
*325	Zola, "Using Monoclonal Antibodies: Soluble Antigens" <u>Monoclonal Antibodies: A Manual of Techniques</u> , CRC Press, Chapter 6, pps. 147-158 (1987)
*326	Zoller and Smith., "Oligonucleotide-Directed Mutagenesis Using M13-Derived Vectors: An Efficient and General Procedure for the Production of Point Mutations in Any Fragment of DNA." <u>Nucl. Acids Res.</u> 10(20):6487-6500 (1982)

Examiner

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



In re Application of: Avi J. Ashkenazi  
Serial No.: 10/081,280  
Filed On: February 21, 2002  
Mailed On: 7 May 2002

Docket No.: P1007R1C1  
By: Diane L. Marschang  
Reg. No.: 35,600

The following has been received in the U.S. Patent Office on the date stamped:

- Transmittal
- Information Disclosure Statement
- Form 1449 with 6 References
- Certificate of Express Mailing
- Express Mail Label No.: EV 016055917 US






**RECEIVED**

MAY 16 2002

GENENTECH, INC.  
LEGAL, DEPT.



49  
**GENENTECH, INC.**

1 DNA Way

South San Francisco, CA 94080-4990  
ATTENTION: PATENT DEPARTMENT

© USPS 2002 recycled

**BEST AVAILABLE COPY**



UNITED STATES POSTAL SERVICE®

**ORIGIN (POSTAL USE ONLY)**

PO ZIP Code <i>94080</i>	Day of Delivery <input type="checkbox"/> Next <input type="checkbox"/> Second	Flat Rate Envelope <input type="checkbox"/>
Date <i>57 02</i>	Time In Mo Day Year	Postage \$
Weight <i>1.0 lbs</i>	Military <input type="checkbox"/> 2nd Day <input type="checkbox"/> 3rd Day	Return Receipt Fee
No Delivery <input type="checkbox"/> Weekend <input type="checkbox"/> Holiday	Int'l Alpha Country Code <i>X940899</i>	COD Fee    Insurance Fee
Acceptance Clerk Initials <i>P1007RICK DM/kz</i>		Total Postage & Fees \$

**CUSTOMER USE ONLY**

METHOD OF PAYMENT:  
Express Mail Corporate Acct. No.



EV 016055917 US

SEE REVERSE SIDE FOR  
SERVICE GUARANTEE AND LIMITS  
ON INSURANCE COVERAGE

**WAIVER OF SIGNATURE (Domestic Only):** Additional merchandise insurance is void if waiver of signature is requested. I wish delivery to be made without obtaining signature of addressee or addressee's agent (if delivery employee judges that article can be left in secure location) and I authorize that delivery employee's signature constitutes valid proof of delivery.

NO DELIVERY

Weekend

Holiday

Customer Signature



FROM: (PLEASE PRINT)  
*GENENTECH INC*

PHONE ( *1 800 222 1811* )

1 DNA WAY  
LEGAL DEPARTMENT MS/49  
SOUTH SAN FRANCISCO CA 94080-4990

*P1007RICK DM/kz*

Federal Agency Acct. No. or  
Postal Service Acct. No.

TO: (PLEASE PRINT)  
PHONE ( *1 800 222 1811* )

DIRECTORY OF PATENTS & TRADEMARKS  
WASHINGTON DC 20231-9999

FOR PICKUP OR TRACKING CALL 1-800-222-1811 [www.usps.com](http://www.usps.com)



Customer Copy  
Label 11-F August 2000

BEST AVAILABLE COPY